Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Nov 25:14:58.
doi: 10.5334/tohm.946. eCollection 2024.

Early Levodopa-Induced Motor Complications in RAB39B X-Linked Parkinsonism

Laurane Mackels  1 , David Aktan  2   3 , Frédérique Depierreux  2
Affiliations
Case Reports

Early Levodopa-Induced Motor Complications in RAB39B X-Linked Parkinsonism

Laurane Mackels et al. Tremor Other Hyperkinet Mov (N Y). .

Abstract

Background: While levodopa may benefit some patients with monogenic Parkinson's Disease and parkinsonism, others may exhibit aberrant responses earlier after exposure. Reporting treatment responses in rare genetic parkinsonism will help tailor therapeutic approaches to specific patients subpopulations.

Case report: We report the therapeutic response in a patient with RAB39B X-linked parkinsonism, who exhibited motor and non-motor complications within a few months of Levodopa.

Discussion: Severe and debilitating Levodopa-induced complications can occur very early in the treatment course of X-linked parkinsonism, highlighting the need for an individualized therapeutic approach and follow-up in rare parkinsonian syndromes.

Keywords: Levodopa-induced motor complication; RAB39B; monogenic parkinsonism; synucleinopathy.

PubMed Disclaimer

Conflict of interest statement

FD received funds from the Belgian Fund for Scientific Research (F.R.S-FNRS). LM and DA have no financial conflicts to disclose.

Figures

Brain CT shows bilateral calcifications in CN, white arrows
Figure 1
Brain window of low-dose head CT showing bilateral calcification in CN (white arrows). Figure adapted from a previous article [6].
See this image and copyright information in PMC

References

    1. Rajput A, et al. Levodopa efficacy and pathological basis of Parkinson syndrome. Clinical neuropharmacology. 1990; 13(6): 553–558. DOI: 10.1097/00002826-199012000-00007 - DOI - PubMed
    1. Rajput AH, et al. Clinical–pathological study of levodopa complications. Movement disorders: official journal of the Movement Disorder Society. 2002; 17(2): 289–296. DOI: 10.1002/mds.10031 - DOI - PubMed
    1. Guadagnolo D, et al. Genotype-phenotype correlations in monogenic Parkinson disease: A review on clinical and molecular findings. Frontiers in Neurology. 2021; 12: 648588. DOI: 10.3389/fneur.2021.648588 - DOI - PMC - PubMed
    1. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. The Lancet Neurology. 2006; 5(4): 355–363. DOI: 10.1016/S1474-4422(06)70411-2 - DOI - PubMed
    1. Wickremaratchi M, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinson’s disease. European journal of neurology. 2009; 16(4): 450–456. DOI: 10.1111/j.1468-1331.2008.02514.x - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources